PPBT
Purple Biotech Ltd
Price Chart
Latest Quote
$1.70
-0.06 (-3.41%)
Current Price
| Previous Close | $1.76 |
| Open | $1.77 |
| Day High | $1.78 |
| Day Low | $1.66 |
| Volume | 35,477 |
Stock Information
| Shares Outstanding | 932K |
| Total Debt | $184K |
| Cash Equivalents | $6.43M |
| Net Income | $-26.02M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.58M |
| P/E Ratio | 0.00 |
| EPS (TTM) | $3245.09 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-4.72M |
| Income | $-26.02M |
| Book/sh | $10.00 |
| Cash/sh | $6.89 |
| Employees | 10 |
Financial Ratios
| Quick Ratio | 1.40 |
| Current Ratio | 1.48 |
| Debt/Eq | 1.90 |
Returns & Margins
| ROA | -19.55% |
| ROE | -123.35% |
Ownership
| Insider Ownership | 3.73% |
| Institutional Ownership | 6.56% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.93 |
| P/B | 0.17 |
Analyst Data
| Recommendation | none |
| Target Price | $30.00 |
Technical Indicators
| SMA20 | $2.55 |
| SMA50 | $3.52 |
| SMA200 | $5.59 |
| RSI | 21.83 |
| ATR | 0.3034 |
| Shares Float | 925K |
| Short Float | 5.27% |
| Short Ratio | 0.16 |
| Volatility | -0.54 |
| Rel Volume | 0.06 |
Performance History
| Week | +10.39% |
| Month | -51.57% |
| Quarter | -55.13% |
| 6 Months | -77.30% |
| YTD | -74.24% |
| Year | -93.09% |
| 3 Years | -99.48% |
| 5 Years | -99.83% |
| 10 Years | -99.98% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.70 | 35,200 |
| 2026-06-17 | $1.76 | 116,000 |
| 2026-06-16 | $1.64 | 90,700 |
| 2026-06-15 | $1.69 | 374,800 |
| 2026-06-12 | $1.58 | 354,600 |
| 2026-06-11 | $1.54 | 10,509,800 |
| 2026-06-10 | $2.96 | 3,200 |
| 2026-06-09 | $2.99 | 19,300 |
| 2026-06-08 | $2.92 | 20,500 |
| 2026-06-05 | $2.97 | 8,400 |
| 2026-06-04 | $3.09 | 8,100 |
| 2026-06-03 | $2.95 | 8,300 |
| 2026-06-02 | $3.01 | 11,900 |
| 2026-06-01 | $2.99 | 17,700 |
| 2026-05-29 | $2.99 | 19,900 |
| 2026-05-28 | $2.81 | 14,000 |
| 2026-05-27 | $2.98 | 33,800 |
| 2026-05-26 | $2.90 | 50,900 |
| 2026-05-22 | $2.88 | 47,500 |
| 2026-05-21 | $2.70 | 112,300 |
| 2026-05-20 | $2.98 | 6,321,000 |
| 2026-05-19 | $3.51 | 20,200 |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $39,000 | $41,000 | $56,000 | $67,000 |
| Total Expenses | $6,976,000 | $10,803,000 | $22,271,000 | $22,603,000 |
| Other Income Expense | $-18,765,000 | $3,736,000 | $4,001,000 | $307,000 |
| Net Non Operating Interest Income Expense | $-751,000 | $-212,000 | $-1,707,000 | $536,000 |
| Total Other Finance Cost | $939,000 | $431,000 | $2,125,000 | $-71,000 |
| Interest Expense Non Operating | $39,000 | $41,000 | $56,000 | $67,000 |
| Operating Expense | $6,976,000 | $10,803,000 | $22,271,000 | $22,603,000 |
| Other Operating Expenses | $59,000 | $62,000 | $196,000 | $120,000 |
| General And Administrative Expense | $2,983,000 | $2,935,000 | $4,844,000 | $5,962,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-26,386,000 | $-7,240,000 | $-19,880,000 | $-21,668,000 |
| Net Interest Income | $-751,000 | $-212,000 | $-1,707,000 | $536,000 |
| Interest Income | $227,000 | $260,000 | $474,000 | $532,000 |
| Normalized Income | $-7,621,000 | $-10,976,000 | $-23,881,000 | $-21,975,000 |
| Net Income From Continuing And Discontinued Operation | $-26,386,000 | $-7,240,000 | $-19,880,000 | $-21,668,000 |
| Total Operating Income As Reported | $-27,458,000 | $-11,005,000 | $-22,271,000 | $-22,603,000 |
| Net Income Common Stockholders | $-26,386,000 | $-7,240,000 | $-19,880,000 | $-21,668,000 |
| Net Income | $-26,386,000 | $-7,240,000 | $-19,880,000 | $-21,668,000 |
| Net Income Including Noncontrolling Interests | $-26,492,000 | $-7,279,000 | $-19,977,000 | $-21,760,000 |
| Net Income Continuous Operations | $-26,492,000 | $-7,279,000 | $-19,977,000 | $-21,760,000 |
| Pretax Income | $-26,492,000 | $-7,279,000 | $-19,977,000 | $-21,760,000 |
| Special Income Charges | $-20,482,000 | $-202,000 | $0 | $0 |
| Interest Income Non Operating | $227,000 | $260,000 | $474,000 | $532,000 |
| Operating Income | $-6,976,000 | $-10,803,000 | $-22,271,000 | $-22,603,000 |
| Depreciation Amortization Depletion Income Statement | $203,000 | $186,000 | $197,000 | $201,000 |
| Depreciation And Amortization In Income Statement | $203,000 | $186,000 | $197,000 | $201,000 |
| Depreciation Income Statement | $203,000 | $186,000 | $197,000 | $201,000 |
| Net Income Discontinuous Operations | - | - | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $-54.00 | $-44.16 | $-178.00 | $-240.00 |
| Basic EPS | $-54.00 | $-44.16 | $-178.00 | $-240.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-7,485,000 | $-10,788,000 | $-23,725,000 | $-21,799,000 |
| Total Unusual Items | $-18,765,000 | $3,736,000 | $4,001,000 | $307,000 |
| Total Unusual Items Excluding Goodwill | $-18,765,000 | $3,736,000 | $4,001,000 | $307,000 |
| Reconciled Depreciation | $203,000 | $186,000 | $197,000 | $201,000 |
| EBITDA (Bullshit earnings) | $-26,250,000 | $-7,052,000 | $-19,724,000 | $-21,492,000 |
| EBIT | $-26,453,000 | $-7,238,000 | $-19,921,000 | $-21,693,000 |
| Diluted Average Shares | $480,053 | $163,979 | $110,666 | $90,405 |
| Basic Average Shares | $480,053 | $163,957 | $110,666 | $90,405 |
| Diluted NI Availto Com Stockholders | $-26,386,000 | $-7,240,000 | $-19,880,000 | $-21,668,000 |
| Minority Interests | $106,000 | $39,000 | $97,000 | $92,000 |
| Write Off | $20,482,000 | $202,000 | $0 | $0 |
| Gain On Sale Of Security | $1,717,000 | $3,938,000 | $4,001,000 | $307,000 |
| Research And Development | $3,731,000 | $7,620,000 | $17,034,000 | $16,320,000 |
| Selling General And Administration | $2,983,000 | $2,935,000 | $4,844,000 | $5,962,000 |
| Other Gand A | $1,246,000 | $918,000 | $1,150,000 | $1,321,000 |
| Salaries And Wages | $1,737,000 | $2,017,000 | $3,694,000 | $4,641,000 |
| Tax Provision | - | - | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,354,000 | $5,018,000 | $6,163,000 | $26,227,000 |
| Total Assets | $17,572,000 | $37,038,000 | $44,302,000 | $54,622,000 |
| Total Non Current Assets | $7,706,000 | $28,130,000 | $28,514,000 | $21,366,000 |
| Goodwill And Other Intangible Assets | $7,360,000 | $27,842,000 | $28,044,000 | $20,684,000 |
| Other Intangible Assets | $7,360,000 | $27,842,000 | $28,044,000 | - |
| Current Assets | $9,866,000 | $8,908,000 | $15,788,000 | $33,256,000 |
| Other Current Assets | $137,000 | $109,000 | $171,000 | $146,000 |
| Receivables | $155,000 | $275,000 | $205,000 | $997,000 |
| Other Receivables | $155,000 | $275,000 | $205,000 | $997,000 |
| Cash Cash Equivalents And Short Term Investments | $9,574,000 | $8,524,000 | $15,412,000 | $32,113,000 |
| Cash And Cash Equivalents | $8,717,000 | $7,401,000 | $14,489,000 | $15,030,000 |
| Prepaid Assets | - | - | $205,000 | $997,000 |
| Cash Financial | - | - | $14,489,000 | $15,030,000 |
| Non Current Prepaid Assets | - | - | - | $0 |
| Debt | ||||
| Total Debt | $244,000 | $183,000 | $351,000 | $515,000 |
| Current Debt And Capital Lease Obligation | $244,000 | $183,000 | $188,000 | $194,000 |
| Long Term Debt And Capital Lease Obligation | - | $0 | $163,000 | $321,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $7,913,000 | $4,127,000 | $10,005,000 | $7,524,000 |
| Total Non Current Liabilities Net Minority Interest | $160,000 | $140,000 | $304,000 | $466,000 |
| Current Liabilities | $7,753,000 | $3,987,000 | $9,701,000 | $7,058,000 |
| Other Current Liabilities | $4,066,000 | $1,149,000 | $2,518,000 | - |
| Payables And Accrued Expenses | $3,443,000 | $2,655,000 | $6,995,000 | $6,864,000 |
| Payables | $2,415,000 | $1,837,000 | $4,205,000 | $2,830,000 |
| Other Payable | $20,000 | $65,000 | $53,000 | $91,000 |
| Accounts Payable | $2,070,000 | $1,455,000 | $3,532,000 | $2,132,000 |
| Derivative Product Liabilities | - | - | $2,518,000 | $0 |
| Equity | ||||
| Common Stock Equity | $9,714,000 | $32,860,000 | $34,207,000 | $46,911,000 |
| Total Equity Gross Minority Interest | $9,659,000 | $32,911,000 | $34,297,000 | $47,098,000 |
| Stockholders Equity | $9,714,000 | $32,860,000 | $34,207,000 | $46,911,000 |
| Other Equity Interest | $28,408,000 | $30,020,000 | $38,555,000 | $38,181,000 |
| Gains Losses Not Affecting Retained Earnings | $-98,000 | $-98,000 | $-79,000 | $-104,000 |
| Other Equity Adjustments | $-98,000 | $-98,000 | $-79,000 | $-104,000 |
| Retained Earnings | $-171,079,000 | $-144,693,000 | $-137,453,000 | $-117,573,000 |
| Other | ||||
| Treasury Shares Number | $1 | $1 | $1 | $1 |
| Ordinary Shares Number | $1,858,911,800 | $517,128,716 | $252,379,217 | $184,815,091 |
| Share Issued | $1,858,911,801 | $517,128,717 | $252,379,218 | $184,815,092 |
| Tangible Book Value | $2,354,000 | $5,018,000 | $6,163,000 | $26,227,000 |
| Invested Capital | $9,714,000 | $32,860,000 | $34,207,000 | $46,911,000 |
| Working Capital | $2,113,000 | $4,921,000 | $6,087,000 | $26,198,000 |
| Capital Lease Obligations | $244,000 | $183,000 | $351,000 | $515,000 |
| Total Capitalization | $9,714,000 | $32,860,000 | $34,207,000 | $46,911,000 |
| Minority Interest | $-55,000 | $51,000 | $90,000 | $187,000 |
| Additional Paid In Capital | $152,483,000 | $147,631,000 | $133,184,000 | $126,407,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Employee Benefits | $160,000 | $140,000 | $141,000 | $145,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $160,000 | $140,000 | $141,000 | $145,000 |
| Current Capital Lease Obligation | $244,000 | $183,000 | $188,000 | $194,000 |
| Current Accrued Expenses | $1,028,000 | $818,000 | $2,790,000 | $4,034,000 |
| Dueto Related Parties Current | $325,000 | $317,000 | $620,000 | $607,000 |
| Net PPE | $346,000 | $288,000 | $470,000 | $682,000 |
| Gross PPE | $346,000 | $288,000 | $470,000 | $682,000 |
| Other Properties | $124,000 | $124,000 | $154,000 | $215,000 |
| Buildings And Improvements | $222,000 | $164,000 | $316,000 | $467,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $857,000 | $1,123,000 | $923,000 | $17,083,000 |
| Long Term Capital Lease Obligation | - | $0 | $163,000 | $321,000 |
| Investments And Advances | - | - | - | $0 |
| Other Investments | - | - | - | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-5,659,000 | $-14,367,000 | $-19,928,000 | $-16,963,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-5,656,000 | $-14,367,000 | $-19,925,000 | $-16,735,000 |
| Cash Flow From Continuing Operating Activities | $-5,656,000 | $-14,367,000 | $-19,925,000 | $-16,735,000 |
| Cash From Discontinued Operating Activities | - | - | $0 | $0 |
| Investing Activities | ||||
| Capital Expenditure | $-3,000 | - | $-3,000 | $-228,000 |
| Investing Cash Flow | $632,000 | $509,000 | $13,881,000 | $19,914,000 |
| Cash Flow From Continuing Investing Activities | $632,000 | $509,000 | $13,881,000 | $19,914,000 |
| Cash From Discontinued Investing Activities | - | - | - | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $3,153,000 | $5,809,000 | $1,563,000 | $1,498,000 |
| Financing Cash Flow | $6,333,000 | $6,774,000 | $5,449,000 | $1,114,000 |
| Cash Flow From Continuing Financing Activities | $6,333,000 | $6,774,000 | $5,449,000 | $1,114,000 |
| Net Other Financing Charges | $-820,000 | $-836,000 | $-890,000 | $-152,000 |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $3,153,000 | $5,809,000 | $1,563,000 | $1,498,000 |
| Common Stock Issuance | $3,153,000 | $5,809,000 | $1,563,000 | $1,498,000 |
| Cash From Discontinued Financing Activities | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-217,000 | $-183,000 | $-168,000 | $-165,000 |
| End Cash Position | $8,717,000 | $7,401,000 | $14,489,000 | $15,030,000 |
| Beginning Cash Position | $7,401,000 | $14,489,000 | $15,030,000 | $10,890,000 |
| Effect Of Exchange Rate Changes | $7,000 | $-4,000 | $54,000 | $-153,000 |
| Changes In Cash | $1,309,000 | $-7,084,000 | $-595,000 | $4,293,000 |
| Interest Paid Cff | $-23,000 | $-44,000 | $-56,000 | $-67,000 |
| Proceeds From Stock Option Exercised | $4,240,000 | $2,028,000 | $5,000,000 | $0 |
| Net Issuance Payments Of Debt | $-217,000 | $-183,000 | $-168,000 | $-165,000 |
| Net Long Term Debt Issuance | $-217,000 | $-183,000 | $-168,000 | $-165,000 |
| Long Term Debt Payments | $-217,000 | $-183,000 | $-168,000 | $-165,000 |
| Interest Received Cfi | $186,000 | $320,000 | $755,000 | $324,000 |
| Net Investment Purchase And Sale | $449,000 | $189,000 | $16,678,000 | $19,818,000 |
| Sale Of Investment | $458,000 | $189,000 | $16,678,000 | $19,818,000 |
| Purchase Of Investment | $-9,000 | - | - | - |
| Net Business Purchase And Sale | $0 | $0 | $-3,549,000 | $0 |
| Purchase Of Business | $0 | $0 | $-3,549,000 | $0 |
| Net PPE Purchase And Sale | $-3,000 | $0 | $-3,000 | $-26,000 |
| Purchase Of PPE | $-3,000 | $0 | $-3,000 | $-26,000 |
| Change In Working Capital | $808,000 | $-4,332,000 | $274,000 | $3,255,000 |
| Change In Other Current Assets | $153,000 | $96,000 | $178,000 | $313,000 |
| Change In Payables And Accrued Expense | $655,000 | $-4,428,000 | $258,000 | $2,931,000 |
| Change In Payable | $655,000 | $-4,428,000 | $258,000 | $2,931,000 |
| Change In Account Payable | $450,000 | $-2,076,000 | $1,334,000 | $799,000 |
| Other Non Cash Items | $-966,000 | $-3,726,000 | $-2,294,000 | $-843,000 |
| Stock Based Compensation | $309,000 | $582,000 | $1,875,000 | $2,412,000 |
| Asset Impairment Charge | $20,482,000 | $202,000 | $0 | $0 |
| Depreciation Amortization Depletion | $203,000 | $186,000 | $197,000 | $201,000 |
| Depreciation And Amortization | $203,000 | $186,000 | $197,000 | $201,000 |
| Depreciation | $203,000 | $186,000 | $197,000 | $201,000 |
| Net Income From Continuing Operations | $-26,492,000 | $-7,279,000 | $-19,977,000 | $-21,760,000 |
| Net Intangibles Purchase And Sale | - | $0 | $0 | $-202,000 |
| Purchase Of Intangibles | - | $0 | $0 | $-202,000 |
| Change In Other Working Capital | - | - | $-162,000 | $11,000 |
| Sale Of Business | - | - | - | $0 |
| Change In Receivables | - | - | - | $313,000 |
| Changes In Account Receivables | - | - | - | $313,000 |
| Cash Flow From Discontinued Operation | - | - | - | - |
Fetched: 2026-06-17